149 related articles for article (PubMed ID: 37225510)
1. [A case of recurrent non embolic stroke with non-fluent aphasia due to polycythemia vera].
Oguro H; Takahashi T
Nihon Ronen Igakkai Zasshi; 2023; 60(2):177-183. PubMed ID: 37225510
[TBL] [Abstract][Full Text] [Related]
2. Ischemic stroke as an initial performance of polycythemia vera in young adults: A case report and literature review.
Hui S; Zhao J; Huo T; Dong L; Xie Y; Wang X; Zhang M
Medicine (Baltimore); 2024 Feb; 103(7):e36953. PubMed ID: 38363912
[TBL] [Abstract][Full Text] [Related]
3. A case report of cerebral infarction caused by polycythemia vera.
Ren S; Gao F; Chen Z; Wang Z
Medicine (Baltimore); 2018 Dec; 97(52):e13880. PubMed ID: 30593195
[TBL] [Abstract][Full Text] [Related]
4. A Case of Recurrent Ischemic Stroke Involving Subacute, Progressive Intracranial Cerebral Arterial Sclerosis Prior to Diagnosis with JAK2-mutated Polycythemia Vera.
Nezu T; Aoki S; Ochi K; Sugihara S; Takahashi T; Hosomi N; Maruyama H; Matsumoto M
J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):e4-6. PubMed ID: 26432562
[TBL] [Abstract][Full Text] [Related]
5. Cerebral Hemorrhage of a 50-Year-Old Female Patient with Polycythemia Vera.
Chen L; Xiao H; Hu Z
J Stroke Cerebrovasc Dis; 2019 Aug; 28(8):e110-e112. PubMed ID: 31126786
[TBL] [Abstract][Full Text] [Related]
6. [Carotid thrombus and cerebral infarction as the initial clinical manifestation of polycythemia vera].
Sanahuja J; Marti-Fabregas J; Marti-Vilalta JL
Neurologia; 2005 May; 20(4):194-6. PubMed ID: 15891949
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Stroke in a Ghanaian Patient With Polycythemia.
Berchie PO; Sarfo FS; Opare-Sem OK; Ovbiagele B
J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):850-852. PubMed ID: 30595510
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Maffioli M; Mora B; Passamonti F
Clin Adv Hematol Oncol; 2017 Sep; 15(9):700-707. PubMed ID: 28949941
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.
Crodel CC; Jentsch-Ullrich K; Reiser M; Jacobasch L; Sauer A; Tesch H; Ulshöfer T; Wunschel R; Palandri F; Heidel FH
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2693-2705. PubMed ID: 34807311
[TBL] [Abstract][Full Text] [Related]
11. [The diagnosis and treatment of polycythemia rubra vera manifesting as acute cerebral stroke].
Meng R; Zhou J; Ji XM; Li LM; Jia JP; Yang BF
Zhonghua Nei Ke Za Zhi; 2006 May; 45(5):366-8. PubMed ID: 16780735
[TBL] [Abstract][Full Text] [Related]
12. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
13. [Recent advances in polycythemia vera treatment].
Edahiro Y
Rinsho Ketsueki; 2020; 61(9):1187-1194. PubMed ID: 33162515
[TBL] [Abstract][Full Text] [Related]
14. New Therapeutic Approaches in Polycythemia Vera.
Falchi L; Newberry KJ; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S27-33. PubMed ID: 26297275
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
16. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
17. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
18. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
[TBL] [Abstract][Full Text] [Related]
19. Second line therapies in polycythemia vera: What is the optimal strategy after hydroxyurea failure?
Nazha A; Khoury JD; Verstovsek S; Daver N
Crit Rev Oncol Hematol; 2016 Sep; 105():112-7. PubMed ID: 27401783
[TBL] [Abstract][Full Text] [Related]
20. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
